{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T11:32:36Z","timestamp":1786361556113,"version":"build-2736575974"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Multiple myeloma is a malignancy of clonal plasma cells characterized by progressive bone marrow infiltration, commonly presenting with anemia, bone pain, hypercalcemia, and renal dysfunction. T-cell bispecific antibodies (TCBs) have emerged as an effective therapeutic option in relapsed and refractory multiple myeloma, with G-coupled protein receptor, family C, group 5, member D (GPRC5D) representing a promising target due to its high expression in myeloma cells and limited presence in normal tissues. Forimtamig is a next-generation GPRC5D-targeting TCB with a novel 2:1 binding format \u2013 bivalently engaging GPRC5D and monovalently binding CD3\u03b5 on T cells. This structural advantage enhances avidity, stabilizes immunological synapses, and enables potent T-cell activation and cytotoxicity, even against low-antigen-expressing cells in immunosuppressive bone marrow environments. Preclinical studies show that forimtamig outperforms earlier 1\u00a0+\u00a01 TCB formats by 50\u2013200-fold in cell-killing efficiency. When combined with standard agents such as daratumumab, pomalidomide, or cereblon E3 ligase modulatory drugs, forimtamig has shown improved tumor clearance and reduced relapse rates. Its design also minimizes tumor escape by targeting the N-terminal region of GPRC5D. Currently undergoing phase 1 trials, forimtamig is being evaluated both as monotherapy and in combination regimens. Its high potency, favorable safety, and durable immune engagement make it a promising candidate in the evolving treatment landscape of multiple myeloma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ms9.0000000000004952","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T19:01:40Z","timestamp":1778007700000},"page":"3022-3023","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Forimtamig: a potent GPRC5D-targeted bispecific antibody in multiple myeloma"],"prefix":"10.1097","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7894-8397","authenticated-orcid":false,"given":"Hafsa","family":"Ali","sequence":"first","affiliation":[{"name":"Department of Medicine, Sindh Medical College, Jinnah Sindh Medical University, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6715-1946","authenticated-orcid":false,"given":"Hiba","family":"Hilal","sequence":"additional","affiliation":[{"name":"Department of Medicine, Karachi Medical & Dental College, North Nazimabad, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2591-4227","authenticated-orcid":false,"given":"Maliha","family":"Gul","sequence":"additional","affiliation":[{"name":"Department of Medicine, Khyber Girls Medical College, Hayatabad, Peshawar, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6253-876X","authenticated-orcid":false,"given":"Maham","family":"Asad","sequence":"additional","affiliation":[{"name":"Department of Medicine, Karachi Medical & Dental College, North Nazimabad, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1366-2375","authenticated-orcid":false,"given":"Mohammed Hammad","family":"Jaber Amin","sequence":"additional","affiliation":[{"name":"Department of Medicine, Faculty of Medicine, Alzaiem Alazhari University, Khartoum, Sudan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"R1-20260810","first-page":"1815\u201322","article-title":"A unique MUC1-2-VNTR DNA vaccine suppresses tumor growth and prolongs survival in a murine multiple myeloma model","volume":"27","author":"Weng","year":"2012","journal-title":"Oncol Rep"},{"key":"R2-20260810","doi-asserted-by":"crossref","first-page":"202\u201319","DOI":"10.1182\/blood.2024025987","article-title":"Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma","volume":"145","author":"Eckmann","year":"2025","journal-title":"Blood"},{"key":"R3-20260810","doi-asserted-by":"crossref","first-page":"1196\u2013206","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-Targeted CAR T Cells for Myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N Engl J Med"},{"key":"R4-20260810","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-024-01611-z","article-title":"Targeting GPRC5D for multiple myeloma therapy","volume":"17","author":"Zhou","year":"2024","journal-title":"J Hematol Oncol"},{"key":"R5-20260810","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13045-023-01489-3","article-title":"Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting","volume":"16","author":"Zhao","year":"2023","journal-title":"J Hematol Oncol"},{"key":"R6-20260810","doi-asserted-by":"crossref","first-page":"2295\u2013306","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"},{"key":"R7-20260810","doi-asserted-by":"crossref","first-page":"2232\u201344","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-Cell-Redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"key":"R8-20260810","first-page":"20","article-title":"Characterization of dysgeusia and xerostomia in patients with multiple myeloma treated with the T-cell redirecting GPRC5D bispecific antibody talquetamab","volume":"32","author":"Laheij","year":"2023","journal-title":"Support Care Cancer"},{"key":"R9-20260810","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41408-023-00966-9","article-title":"GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review","volume":"14","author":"Rodriguez-Otero","year":"2024","journal-title":"Blood Cancer J"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000004952","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T11:02:17Z","timestamp":1786359737000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000004952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":9,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000004952","relation":{},"ISSN":["2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"assertion":[{"value":"2026-02-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}